EGFR and head and neck squamous cell carcinoma: To date, the only FDA-approved oncogene-targeted therapy is cetuximab (Ctx; Erbitux), a monoclonal antibody that is directed against the epidermal growth factor receptor (EGFR), which is overexpressed in up to 90% of HNSCC tumors [3,8,12–14].